Day: February 28, 2024

    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million, $1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 2024 Total Revenues Guidance of Between $455 Million and $475 Million Conference Call and Webcast to be Held on February 29, 2024, at 8:30 AM ET CORAL GABLES, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: “We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-refractory acute graft-versus-host disease (SR-aGVHD) ahead of our upcoming meeting in March we have provided the FDA with new data from a second potency...

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr. Frederic Guerard as CEO, Peter Lang as CFO, and Dr. Arshad M. Khanani as Chief Medical Advisor Cash and cash equivalents of $157.1 million as of December 31, 2023 MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates. “It is a transformative time for Opthea. We substantially advanced the development of sozinibercept,...

2023 HighlightsNet revenue of $5.1 billion in 2023, an increase of 13.7% over 2022 Adjusted diluted EPS1 of $3.67, an increase of 17.3% over 2022 Backlog of $6.3 billion, up 6.8% since December 31, 2022 Ranked #9 of the most sustainable corporations in the world by Corporate Knights, first among peersEDMONTON, Alberta and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — TSX, NYSE:STN Stantec, a global leader in sustainable design and engineering, today reported its results for the fourth quarter and year ended December 31, 2023. Stantec achieved record financial results and delivered another solid year of excellent performance in 2023. Net revenue increased $609 million to $5.1 billion, driven primarily by 9.9% organic growth1 and 1.5% acquisition growth1. Continued focus on strong project execution and operational excellence drove...

Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million...

Company focused on adenosine platform clinical development WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors. The trial is progressing well with eight academic center clinical sites enrolling patients. The Phase 1a dose escalation portion of the trial has progressed to the third cohort. The Company looks forward to making a clinical update at the 2024 American Society of Clinical Oncology...